Alberta Blue Cross Flags MASH, Sleep Apnea as Next GLP-1 Uses

Alberta Blue Cross's 2026 drug pipeline report says glucagon-like peptide-1 therapies remain a major cost driver for private drug plans in Canada, with future expanded uses potentially including metabolic dysfunction-associated steatohepatitis (MASH) and obstructive sleep apnea (OSA) [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php].

A 'second wave' of GLP-1 development

The insurer's 2026 pipeline report, which reviewed more than 440 new drug and supplemental submissions made to Health Canada in 2025, describes what it calls a second wave of GLP-1 innovation [Source: benefitscanada.com/benefits/health-benefits/expanded-use-of-glp-1s-a-major-driver-of-drug-plan-costs-in-2026-report/]. According to Alberta Blue Cross, emerging therapies in this class are expected to be more effective, have broader uses, last longer between doses and will increasingly be available in oral form [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php].

While GLP-1 therapies such as Ozempic, Wegovy, Mounjaro and Zepbound are already well established in the Canadian market, the report notes that the 2026 pipeline reflects a focus on improved efficacy, more uses and longer dosing intervals [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php].

Generic semaglutide not expected to reverse cost trend

A semaglutide generic is expected in mid-2026, according to the Alberta Blue Cross report [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]. However, the insurer states that overall GLP-1 therapy plan spend is unlikely to decline in future years due to growing use and continued expansion of GLP-1 therapies [Source: benefitscanada.com/benefits/health-benefits/expanded-use-of-glp-1s-a-major-driver-of-drug-plan-costs-in-2026-report/].

The patient-facing digital pharmacy Felix has published an indicative generic pricing ladder based on Canada's generic drug framework, suggesting a first generic could arrive at roughly $240 per pen, two generics at $160 per pen, and three or more generics at $112 per pen, compared with a stated brand reference of $320 per pen [Source: felixforyou.ca/generic-semaglutide-waitlist]. Those figures are illustrative estimates from a third party and sit below current pharmacy prices tracked by GLP1Prices.ca, where Ozempic listings range from $222 to $663 CAD across 148 samples. Shoppers can monitor applications on our generic semaglutide tracker.

Oral formulations enter the picture

The pipeline report's emphasis on oral GLP-1 products lands shortly after Health Canada's authorization of the first GLP-1 daily pill in Canada. Novo Nordisk announced that Rybelsus, a once-a-day semaglutide pill, received a new Health Canada authorization, with all other GLP-1 drugs available in Canada to date being injectables [Source: globalnews.ca/news/11609231/health-canada-glp-1-pill-rybelsus].

Novo Nordisk has also applied to bring a separate pill form of Wegovy to Canada, according to Global News [Source: globalnews.ca/news/11609231/health-canada-glp-1-pill-rybelsus]. In the United States, the oral Wegovy pill hit the market at a cost of US$149 a month or around US$5 a day about two weeks after FDA approval [Source: globalnews.ca/news/11609231/health-canada-glp-1-pill-rybelsus].

What plan sponsors are watching

Alberta Blue Cross identifies several factors shaping GLP-1 plan costs through 2026:

• Expanded potential uses beyond diabetes and obesity, including MASH and OSA [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
• A robust pipeline of new GLP-1 therapies under development [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
• Shift toward longer-acting and oral formulations [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
• A semaglutide generic expected mid-2026 [Source: benefitscanada.com/benefits/health-benefits/expanded-use-of-glp-1s-a-major-driver-of-drug-plan-costs-in-2026-report/]

Canadians assessing their options can review our insurance coverage checker or visit the FAQ for pricing and regulatory context.

This article is for informational purposes only and does not constitute medical advice.